CA2496948A1 - Il-14 vaccine for the treatment of asthma and atopic disorders - Google Patents

Il-14 vaccine for the treatment of asthma and atopic disorders Download PDF

Info

Publication number
CA2496948A1
CA2496948A1 CA002496948A CA2496948A CA2496948A1 CA 2496948 A1 CA2496948 A1 CA 2496948A1 CA 002496948 A CA002496948 A CA 002496948A CA 2496948 A CA2496948 A CA 2496948A CA 2496948 A1 CA2496948 A1 CA 2496948A1
Authority
CA
Canada
Prior art keywords
vaccine
immunogen
human
sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496948A
Other languages
English (en)
French (fr)
Inventor
Jonathan Henry Ellis
Claire Ashman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220211A external-priority patent/GB0220211D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Individual filed Critical Individual
Publication of CA2496948A1 publication Critical patent/CA2496948A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002496948A 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders Abandoned CA2496948A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0220211.7 2002-08-30
GB0220211A GB0220211D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
GB0304672.9 2003-02-28
PCT/GB2003/003729 WO2004019975A2 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Publications (1)

Publication Number Publication Date
CA2496948A1 true CA2496948A1 (en) 2004-03-11

Family

ID=31980002

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002496948A Abandoned CA2496948A1 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders
CA002496607A Abandoned CA2496607A1 (en) 2002-08-30 2003-08-28 Vaccine comprising il-13 and an adjuvant

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002496607A Abandoned CA2496607A1 (en) 2002-08-30 2003-08-28 Vaccine comprising il-13 and an adjuvant

Country Status (6)

Country Link
US (1) US20060104943A1 (enExample)
EP (2) EP1534323A2 (enExample)
JP (2) JP2006501249A (enExample)
AU (2) AU2003259374A1 (enExample)
CA (2) CA2496948A1 (enExample)
WO (2) WO2004019975A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
SE532249C2 (sv) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering
WO2008109957A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Method for determining suitability of treatment for asthma or chronic airways disease
EP2117586B1 (en) * 2007-03-15 2018-08-08 Hunter Immunology Pty Ltd Treatment or prophylaxis of asthma
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Also Published As

Publication number Publication date
AU2003260748A8 (en) 2004-03-19
JP2006501249A (ja) 2006-01-12
AU2003260748A1 (en) 2004-03-19
WO2004019979A3 (en) 2004-07-08
CA2496607A1 (en) 2004-03-11
WO2004019979A2 (en) 2004-03-11
AU2003259374A8 (en) 2004-03-19
WO2004019975A3 (en) 2004-07-08
AU2003259374A1 (en) 2004-03-19
JP2006503018A (ja) 2006-01-26
EP1534329A2 (en) 2005-06-01
US20060104943A1 (en) 2006-05-18
EP1534323A2 (en) 2005-06-01
WO2004019975A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
TWI387463B (zh) Ｉｇｅ ｃｈ３肽疫苗
TWI461209B (zh) 包含抗原tau肽之免疫原及其組合物
US20060147417A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP4238031B2 (ja) ワクチン
EP1534323A2 (en) Il-14 vaccine for the treatment of asthma and atopic disorders
AU2002233560A1 (en) Vaccine
TW201309327A (zh) 疫苗
BR112020016373A2 (pt) Composição imunogênica compreendendo antígenos de estafilococos
KR102101201B1 (ko) Ｐｃｓｋ9 펩티드 백신
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
CA2548512A1 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
JP2022544407A (ja) 免疫原性組成物
TW201348264A (zh) 組成物

Legal Events

Date Code Title Description
FZDE Discontinued